Nightingale Health Plc | Inside Information | June 08, 2026 at 19:25:00 EEST
Nightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF), a pioneer in disease risk detection and preventive health, will not reach its previously communicated milestone of more than 50% revenue growth for the current financial year compared with the previous financial year. The reason is a shift in the timeline of a major project announced on September 16, 2025, with contract value of EUR 2.4 million. The timeline is shifted for reasons outside the company's control, which moves approximately EUR 2 million of revenue into the next financial year. The project will be implemented in full scope, and Nightingale Health still expects current-year revenue to grow by approximately 20% (+/- 5%) compared with the previous financial year.
The previously communicated target of more than 50% revenue growth for the current financial year will not be reached because the timeline of a major project has shifted for reasons outside the company's control. The project will proceed and be implemented in full scope. The associated revenue, approximately EUR 2 million, will be recognised in the next financial year rather than the current one. This is a shift in timing, not a change to the project or its total value.
Despite the approximately EUR 2 million of project revenue shifting to the next financial year, Nightingale Health still expects current-year revenue to grow by approximately 20% (+/- 5%) compared with the previous financial year. Had the postponed project revenue been recognised in the current financial year as originally planned, the company would have reached revenue growth of approximately 65%. Over the year, Nightingale Health has continued strong sales efforts across both its healthcare and research businesses.
Nightingale Health expects revenue to exceed EUR 10 million in the next financial year. The company will announce more detailed targets for the financial year 2026-2027 as part of its full-year result release in September 2026.
"Not reaching this year's growth target is disappointing, but the reason is timing, not lost business. The project will be delivered in full and the majority of its revenue moves with it into next financial year, while our healthcare and research businesses have continued to grow strongly. We enter the next financial year with real momentum," says Teemu Suna, CEO and Founder of Nightingale Health.
For further information, please contact
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
Chronic diseases cause around 75% of deaths globally and place a growing burden on healthcare systems. The way to address this is preventive healthcare, but until recently the tools to detect disease risks at population scale have not existed. Nightingale Health has built them. The Nightingale Health Check is a blood-based risk detection test that identifies risks for multiple chronic diseases, including cardiovascular disease, type 2 diabetes, kidney disease, and fatty liver disease, from a single blood sample. It is designed to be applied population-wide, so healthcare systems can identify the people who would benefit most from preventive action before disease develops.
Nightingale Health's technology is validated in over 900 peer-reviewed scientific publications and is used in many of the world's leading health studies, including the UK Biobank. In Finland, the Nightingale Health Check is in nationwide healthcare use, and over 200,000 people have already received their results. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 34 countries across healthcare and medical research. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/
Image Attachments
Nightingale Health
